Download MendeleyFree energy perturbation in the design of EED ligands as inhibitors of polycomb repressive complex 2 (PRC2) methyltransferase.
O' Donovan, D.H., Gregson, C., Packer, M.J., Greenwood, R., Pike, K.G., Kawatkar, S., Bloecher, A., Robinson, J., Read, J., Code, E., Hsu, J.H., Shen, M., Woods, H., Barton, P., Fillery, S., Williamson, B., Rawlins, P.B., Bagal, S.K.(2021) Bioorg Med Chem Lett 39: 127904-127904
- PubMed: 33684441
- DOI: https://doi.org/10.1016/j.bmcl.2021.127904
- Primary Citation of Related Structures:
6YVI, 6YVJ - PubMed Abstract:
Free Energy Perturbation (FEP) calculations can provide high-confidence predictions of the interaction strength between a ligand and its protein target. We sought to explore a series of triazolopyrimidines which bind to the EED subunit of the PRC2 complex as potential anticancer therapeutics, using FEP calculations to inform compound design. Combining FEP predictions with a late-stage functionalisation (LSF) inspired synthetic approach allowed us to rapidly evaluate structural modifications in a previously unexplored region of the EED binding site. This approach generated a series of novel triazolopyrimidine EED ligands with improved physicochemical properties and which inhibit PRC2 methyltransferase activity in a cancer-relevant G401 cell line.
Organizational Affiliation:
Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom. Electronic address: daniel.odonovan@astrazeneca.com.
